Vis enkel innførsel

dc.contributor.authorMalmin, Agni
dc.contributor.authorThomseth, Vilde Marie
dc.contributor.authorFørland, Per Tore
dc.contributor.authorKhan, Ayyad Ahmad Zartasht
dc.contributor.authorHetland, Hanne Brit
dc.contributor.authorChen, Xiangjun
dc.contributor.authorHaugen, Inga Britt Kjellevold
dc.contributor.authorUtheim, Tor Paaske
dc.contributor.authorForsaa, Vegard Asgeir
dc.date.accessioned2023-08-23T09:07:27Z
dc.date.available2023-08-23T09:07:27Z
dc.date.created2023-04-20T15:07:49Z
dc.date.issued2023
dc.identifier.citationMalmin, A., Thomseth, V.M., Førland, P.T., Khan, A.Z. Hetland, H.B., Chen, X., Haugen, I-B.K., Utheim, T.P., Forsaa, V.A.(2023) Associations between Serial Intravitreal Injections and Dry Eye. Ophthalmology (Rochester, Minn.), 130 (5), 509-515.en_US
dc.identifier.issn0161-6420
dc.identifier.urihttps://hdl.handle.net/11250/3085382
dc.description.abstractPurpose To investigate the effects of serial intravitreal injections (IVIs) on the ocular surface and meibomian glands (MGs) in patients treated with anti-vascular endothelial growth factor (anti-VEGF) for neovascular age-related macular degeneration (nAMD). Design Retrospective, controlled, observational study. Participants Patients with nAMD receiving unilateral IVIs with anti-VEGF agents. The fellow eye was used as control. Methods Tear film and ocular surface examinations were performed on a single occasion at a minimum of 4 weeks after IVI. A pre-IVI asepsis protocol with povidone-iodine (PVP-I) was applied. Main Outcome Measures Upper and lower MG loss, tear meniscus height (TMH), bulbar redness (BR) score, noninvasive tear break-up time (NIBUT), tear film osmolarity (TOsm), Schirmer test, corneal staining, fluorescein tear film break-up time (TBUT), meibomian gland expressibility (ME), and meibum quality. Results Ninety patients with a mean age of 77.5 years (standard deviation [SD], 8.4; range 54–95) were included. The median number of IVIs in treated eyes was 19.5 (range, 2–132). Mean MG loss in the upper eyelid was 19.1% (SD, 11.3) in treated eyes and 25.5% (SD, 14.6) in untreated fellow eyes (P = 0.001). For the lower eyelid, median MG loss was 17.4% (interquartile range [IQR], 9.4–29.9) in treated eyes and 24.5% (IQR, 14.2–35.2) in fellow eyes (P < 0.001). Mean BR was 1.32 (SD, 0.46) in treated eyes versus 1.44 (SD, 0.45) in fellow eyes (P = 0.017). Median TMH was 0.36 mm (IQR, 0.28–0.52) in treated eyes and 0.32 mm (IQR, 0.24–0.49) in fellow eyes (P = 0.02). There were no differences between treated and fellow eyes regarding NIBUT, TOsm, Schirmer test, corneal staining, fluorescein TBUT, ME, or meibum quality. Conclusions Repeated IVIs with anti-VEGF with preoperative PVP-I application was associated with reduced MG loss, increased tear volume, and reduced signs of inflammation compared with fellow nontreated eyes in patients with nAMD. This regimen may thus have a beneficial effect on the ocular surface.en_US
dc.language.isoengen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectoftalmologien_US
dc.titleAssociations between Serial Intravitreal Injections and Dry Eyeen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2023 by the American Academy of Ophthalmologyen_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Oftalmologi: 754en_US
dc.source.pagenumber509-515en_US
dc.source.volume130en_US
dc.source.journalOphthalmologyen_US
dc.source.issue5en_US
dc.identifier.doi10.1016/j.ophtha.2023.01.009
dc.identifier.cristin2142232
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal